BiotechTube

Perampanel + Placebo

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Epilepsy, Partial

Conditions

Epilepsy, Partial

Trial Timeline

Mar 1, 2015 → Aug 1, 2016

NCT ID
NCT02220972

About Perampanel + Placebo

Perampanel + Placebo is a approved stage product being developed by Eisai for Epilepsy, Partial. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02220972. Target conditions include Epilepsy, Partial.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (4)

NCT IDPhaseStatus
NCT02220972ApprovedWithdrawn
NCT01618695Phase 3Completed
NCT01161524Phase 2Completed
NCT00566462Phase 2Terminated

Competing Products

20 competing products in Epilepsy, Partial

See all competitors
ProductCompanyStageHype Score
perampanelEisaiPhase 2
52
LacosamideUCBPhase 3
74
Zonisamide + PlaceboEisaiPhase 3
77
ZonegranEisaiApproved
85
perampanel + perampanelEisaiPhase 1
33
perampanelEisaiApproved
85
E2007 + PlaceboEisaiPhase 2
52
Placebo + RufinamideEisaiPhase 3
77
E2007 (perampanel) + PlaceboEisaiPhase 2
52
Perampanel Oral TabletEisaiApproved
85
perampanelEisaiPhase 3
77
PerampanelEisaiPre-clinical
23
Zonisamide + CarbamazepineEisaiPhase 3
77
PerampanelEisaiApproved
85
Perampanel and Microgynon-30 + Perampanel and Microgynon-30EisaiPhase 1
33
PerampanelEisaiPhase 2
52
Zonisamide + PlaceboEisaiPhase 3
77
zonisamide low dose group + zonisamide high dose groupEisaiApproved
85
E2007 + E2007 + PlaceboEisaiPhase 2
52
Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved
85

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85